Middle east respiratory syndrome

Yaseen M. Arabi*, Hanan H. Balkhy, Frederick G. Hayden, Abderrezak Bouchama, Thomas Luke, J. Kenneth Baillie, Awad Al-omari, Ali H. Hajeer, Mikiko Senga, Mark R. Denison, Jonathan S. Nguyen-Van-Tam, Nahoko Shindo, Alison Bermingham, James D. Chappell, Maria D. Van Kerkhove, Robert A. Fowler

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

224 Citations (Scopus)

Abstract

Between September 2012 and January 20, 2017, the World Health Organization (WHO) received reports from 27 countries of 1879 laboratory-confirmed cases in humans of the Middle East respiratory syndrome (MERS) caused by infection with the MERS coronavirus (MERS-CoV) and at least 659 related deaths. Cases of MERS-CoV infection continue to occur, including sporadic zoonotic infections in humans across the Arabian Peninsula, occasional importations and associated clusters in other regions, and outbreaks of nonsustained human-To-human transmission in health care settings. Dromedary camels are considered to be the most likely source of animal-To-human transmission. MERS-CoV enters host cells after binding the dipeptidyl peptidase 4 (DPP-4) receptor and the carcinoembryonic antigen-related cell-Adhesion molecule 5 (CEACAM5) cofactor ligand, and it replicates efficiently in the human respiratory epithelium. Illness begins after an incubation period of 2 to 14 days and frequently results in hypoxemic respiratory failure and the need for multiorgan support. However, asymptomatic and mild cases also occur. Real-Time reverse-Transcription-polymerase- chain-reaction (RT-PCR) testing of respiratory secretions is the mainstay for diagnosis, and samples from the lower respiratory tract have the greatest yield among seriously ill patients. There is no antiviral therapy of proven efficacy, and thus treatment remains largely supportive; potential vaccines are at an early developmental stage. There are multiple gaps in knowledge regarding the evolution and transmission of the virus, disease pathogenesis, treatment, and prospects for a vaccine. The ongoing occurrence of MERS in humans and the associated high mortality call for a continued collaborative approach toward gaining a better understanding of the infection both in humans and in animals. MERS-CoV was first identified in September 20121 in a patient from Saudi Arabia who had hypoxemic respiratory failure and multiorgan illness. Subsequent cases have included infections in humans across the Arabian Peninsula, occasional importations and associated clusters in other regions, and outbreaks of nonsustained human-Tohuman transmission in health care settings.

Original languageEnglish
Pages (from-to)584-594
Number of pages11
JournalNew England Journal of Medicine
Volume376
Issue number6
DOIs
Publication statusPublished - 9 Feb 2017

Bibliographical note

Funding Information:
Supported by a Wellcome Trust Intermediate Clinical Fellowship and a Wellcome-Beit Prize (103258/Z/13/Z and 103258/Z/13/A, both to Dr. Baillie), a Biotechnology and Biological Sciences Research Council Institute Strategic Programme Grant (to the Roslin Institute), the Intensive Care Foundation, and an award from the Heart and Stroke Foundation, Ontario Provincial Office (to Dr. Fowler).

Publisher Copyright:
Copyright © 2017 Massachusetts Medical Society. All rights reserved.

Copyright:
Copyright 2017 Elsevier B.V., All rights reserved.

Fingerprint

Dive into the research topics of 'Middle east respiratory syndrome'. Together they form a unique fingerprint.

Cite this